Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERBB2
REST API REST API
Homo sapiens
ERBB2 is differentially expressed in 293 experiments: 154 organism parts: bone marrow, prostate, ... (152 more);, 193 disease states: normal, prostate carcinoma, ... (191 more);, 96 cell types 461 cell lines 46 compound treatments and 79 other conditions.
Synonyms NGL, NEU, CD340, HER2, HER-2
Orthologs Erbb2 (Mus musculus)   erbb2 (Danio rerio)   ERBB2 (Gallus gallus)   ERBB2 (Bos taurus)   Erbb2 (Rattus norvegicus)   LOC100492078 (Xenopus laevis)   ERBB2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, DNA binding, protein binding, positive regulation of translation, regulation of transcription, DNA-dependent, neuromuscular junction development, cytoplasm, microvillus, cell proliferation, epidermal growth factor receptor signaling pathway, wound healing, positive regulation of cell proliferation, membrane, negative regulation of apoptosis, postsynaptic membrane, protein tyrosine kinase activity, positive regulation of MAP kinase activity, membrane raft, transmembrane receptor protein tyrosine kinase signaling pathway, motor axon guidance, endosome membrane, glial cell differentiation, basolateral plasma membrane, identical protein binding, ATP binding, axon guidance, protein dimerization activity, cell surface receptor linked signaling pathway, nucleus, response to axon injury, heart development, protein heterodimerization activity, Hsp90 protein binding, receptor activity, nucleotide binding, protein serine/threonine kinase activity, response to drug, transmembrane receptor protein tyrosine kinase activity, perinuclear region of cytoplasm, nervous system development, apical plasma membrane, integral to membrane, positive regulation of cell growth, protein C-terminus binding, basal plasma membrane, skeletal muscle tissue development, signal transduction, protein kinase activity, peripheral nervous system development, positive regulation of Ras protein signal transduction, ubiquitin protein ligase binding, positive regulation of cell adhesion, receptor signaling protein tyrosine kinase activity, regulation of angiogenesis, myelination, regulation of ERK1 and ERK2 cascade, ErbB-3 class receptor binding, response to progesterone stimulus, mammary gland development, estrus, positive regulation of epithelial cell proliferation, receptor complex, lateral loop, glycoprotein binding, sympathetic nervous system development, growth factor binding, positive regulation of transcription from RNA polymerase I promoter, positive regulation of transcription from RNA polymerase III promoter, regulation of microtubule-based process, liver development, mammary gland involution, protein phosphatase binding, enzyme linked receptor protein signaling pathway, tongue development, positive regulation of MAPKKK cascade, protein autophosphorylation, protein phosphorylation, phosphatidylinositol-mediated signaling, phosphatidylinositol 3-kinase cascade, positive regulation of phosphatidylinositol 3-kinase cascade, negative regulation of immature T cell proliferation in thymus, epidermal growth factor-activated receptor activity, transmembrane signaling receptor activity, RNA polymerase I core binding
InterPro Term Furin-like_Cys-rich_dom, Prot_kinase_cat_dom, EGF_rcpt_L, Furin_repeat, Tyr_kinase_EGF/ERB/XmrK_rcpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q9NP09, B4DTR1, P04626, F5H1T4
Gene-Disease Assocation OVARIAN CANCER, LUNG CANCER, GASTRIC CANCER, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC, GLIOMA SUSCEPTIBILITY 1; GLM1
Search EB-eye ENSG00000141736
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (37 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
primary culture
2
E-GEOD-2450, E-GEOD-1657
BT-474
2
E-GEOD-3529, E-GEOD-5823
HCC1143
2
E-MTAB-62, E-MTAB-37
HCC1954
2
E-MTAB-37, E-GEOD-29119
455 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (45 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
endothelial cell
1
2
E-GEOD-3920, E-GEOD-3998, E-GEOD-19240
bronchial epithelial cell
1
E-TABM-145
germ cell
1
E-MTAB-25
hematopoietic progenitor cells
1
E-MEXP-70
primary fibroblast
1
E-MEXP-66
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, E-MTAB-680, ... (58 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-MTAB-37, E-GEOD-7307 ... (5 experiments)
cervical carcinoma
3
E-MTAB-37, E-MEXP-1331, E-GEOD-5823
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
liver carcinoma
1
E-MTAB-37
187 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, ... (31 experiments)

Factor Value U/D Experiments
none
2
10
E-TABM-782, E-MEXP-1601, E-GEOD-412, E-GEOD-2803, E-GEOD-2292, ... (12 experiments)
17beta-estradiol
4
3
E-GEOD-2292, E-GEOD-4006, E-GEOD-4668
control
2
E-GEOD-3284, E-GEOD-4006
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
TGF
1
E-GEOD-15205
glutamine
1
E-MEXP-1335
40 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, E-GEOD-1563, ... (13 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er ihc
studied in E-GEOD-21653

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-43, E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.402 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM